Phase II study of BKM120 in patients with advanced esophageal squamous cell carcinoma (EPOC1303)

[1]  M. Suntharalingam,et al.  Effect of the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation Therapy for Patients With Esophageal Cancer: The NRG Oncology RTOG 0436 Phase 3 Randomized Clinical Trial , 2017, JAMA oncology.

[2]  Sung-Bae Kim,et al.  Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. , 2017, The Lancet. Oncology.

[3]  I. Treilleux,et al.  Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I–type II study from the GINECO group , 2017, British Journal of Cancer.

[4]  A. Ochiai,et al.  Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma , 2017, BMC Cancer.

[5]  Benjamin J. Raphael,et al.  Integrated genomic characterization of oesophageal carcinoma , 2017, Nature.

[6]  C. Gridelli,et al.  Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[7]  C. Mathers,et al.  Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.

[8]  P. Petrow,et al.  PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients , 2015, Clinical Cancer Research.

[9]  N. Lu,et al.  PIK3CA Gene Mutations and Overexpression: Implications for Prognostic Biomarker and Therapeutic Target in Chinese Esophageal Squamous Cell Carcinoma , 2014, PloS one.

[10]  J. Bendell,et al.  Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors , 2014, Investigational New Drugs.

[11]  M. Robson,et al.  Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors , 2014, Cancer science.

[12]  Razelle Kurzrock,et al.  Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. , 2014, Cell reports.

[13]  A. González-Angulo,et al.  Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. , 2013, Cancer treatment reviews.

[14]  C. Hurt,et al.  Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. , 2013, The Lancet. Oncology.

[15]  H. Baba,et al.  PIK3CA Mutation Is Associated with a Favorable Prognosis among Patients with Curatively Resected Esophageal Squamous Cell Carcinoma , 2013, Clinical Cancer Research.

[16]  Razelle Kurzrock,et al.  PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Jordi Rodon,et al.  Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Razelle Kurzrock,et al.  PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors , 2011, Molecular Cancer Therapeutics.

[19]  M. Wilkerson,et al.  Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. , 2010, Cancer cell.

[20]  F. Lordick,et al.  Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  A. Ohtsu,et al.  Phase I Clinical and Pharmacokinetic Study of RAD001 (Everolimus) Administered Daily to Japanese Patients with Advanced Solid Tumors , 2009, Japanese journal of clinical oncology.

[22]  L. Cantley,et al.  PI3K pathway alterations in cancer: variations on a theme , 2008, Oncogene.

[23]  H. Sasaki,et al.  PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. , 2008, The Journal of surgical research.

[24]  Hans Clevers,et al.  Functional analysis of Peutz-Jeghers mutations reveals that the LKB1 C-terminal region exerts a crucial role in regulating both the AMPK pathway and the cell polarity. , 2005, Human molecular genetics.

[25]  R. DePinho,et al.  The LKB1 tumor suppressor negatively regulates mTOR signaling. , 2004, Cancer cell.

[26]  H. Yamana,et al.  Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). , 2001, Japanese journal of clinical oncology.

[27]  H. Watanabe,et al.  Phase II evaluation of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japanese Esophageal Oncology Group Trial. , 1992, Japanese journal of clinical oncology.

[28]  S. Andreola,et al.  PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.